Ankyra Therapeutics, Inc
Clinical trials sponsored by Ankyra Therapeutics, Inc, explained in plain language.
-
New injection tackles Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various solid cancers…
Phase: PHASE1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated May 17, 2026 03:29 UTC
-
New hope for advanced lung cancer: drug duo aims to shrink tumors
Disease control Recruiting nowThis early-stage study tests a new drug called tolododekin alfa combined with an immunotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. About 60 participants will join, including those wh…
Phase: PHASE1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated May 17, 2026 03:27 UTC